MCL Literature Feed

A rare, non-nodal MCL case with hairy cell-like features and a TP53 mutation showed an indolent course, challenging prognostic assumptions and emphasizing comprehensive genomic and pathologic evaluation.

This case report details severe glofitamab-induced ICANS with seizures in a heavily pre-treated MCL patient, highlighting CNS risk factors and successful management with anakinra and antiseizure drugs.

Brexucabtagene autoleucel (CAR-T) combined with BTK inhibitors is a potentially safe and effective strategy for treating relapsed mantle cell lymphoma with central nervous system involvement.

Real-world registry data from Ukraine (2019-2021) reports a 3-year overall survival of 61% for newly diagnosed MCL patients, providing a crucial benchmark for outcomes in this region.

Combining CAR-T therapy with a BTK inhibitor may offer a synergistic strategy to effectively treat mantle cell lymphoma with central nervous system involvement, a historically poor-prognosis population.

An indirect comparison suggests brexucabtagene autoleucel provides superior response rates and progression-free survival over pirtobrutinib for MCL patients who have failed a prior covalent BTKi.

The PI3Ki zandelisib plus BTKi zanubrutinib combination shows high efficacy (74% ORR, 47% CR) with manageable toxicity in relapsed/refractory MCL, offering a promising chemotherapy-free regimen.

This review provides a framework for integrating bispecific antibodies into MCL treatment, addressing the critical clinical question of how to sequence them with other novel immunotherapies like CAR-T.

The EHA/EBMT ICAHT grading system better predicts severe infections and mortality post-CAR-T than CTCAE, which is highly relevant as MCL patients showed the highest rates of severe hematotoxicity.

MNDA is highly expressed in nearly 80% of mantle cell lymphoma cases, but its utility in distinguishing MCL from marginal zone lymphoma is limited due to overlapping expression.

This preclinical study identifies DNMT3A-mediated metabolic reprogramming to oxidative phosphorylation as a novel ibrutinib resistance mechanism, which can be overcome by low-dose decitabine.

This meta-analysis across B-NHLs confirms lenalidomide-based regimens improve OS and PFS, supporting its established role in relapsed/refractory and maintenance settings for MCL.

This preclinical study identifies that SOX11 upregulates the antioxidant PRDX2, promoting chemoresistance in aggressive MCL, and suggests PRDX2 as a novel therapeutic target to overcome drug resistance.

This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.

A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

The CAR-T therapy lisocabtagene maraleucel demonstrates high, durable complete responses and a favorable safety profile in heavily pretreated, relapsed/refractory MCL, including high-risk patients.

This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.

This case report highlights unprovoked venous thromboembolism as a presenting symptom of mantle cell lymphoma, underscoring the need for a prompt malignancy workup in such clinical scenarios.

This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.

The CRM1 inhibitor KPT-330 induces protective autophagy in MCL cells; co-treatment with an autophagy inhibitor like chloroquine results in synergistic cell killing, suggesting a novel combination strategy.

This narrative review of Malaysian B-cell lymphoma research identifies only three mantle cell lymphoma papers, highlighting a significant data gap and the need for more regional epidemiological studies.

This case report describes the rare Warburg effect (severe hypoglycemia, lactic acidosis) in an MCL patient, highlighting its potential for cardiac toxicity and the utility of hemodialysis for stabilization.

Using computational screening and machine learning, this study identifies novel PIM2 inhibitors, presenting a potential new therapeutic target for future drug development in hematologic malignancies, including MCL.

MCL with concurrent EZH2 expression and TP53 mutation is frequent and identifies a patient subgroup with a dismal outcome, establishing a powerful negative prognostic biomarker combination.

This review, while focused on CLL, details the metabolic and toxicity profiles of covalent and non-covalent BTKis, informing MCL management strategies for adverse events and emerging resistance.

This review summarizes fundamental MCL characteristics, including the t(11;14) translocation and key high-risk features (high Ki67, blastoid variant, TP53 mutation) essential for patient risk stratification.

This paper does not study MCL but finds high Notch1 protein expression in methotrexate-associated DLBCL, suggesting a pathogenic role for this pathway, which is also altered in MCL.

Severe neurotoxicity after brexucabtagene autoleucel is common, associated with MRI/EEG changes and longer hospitalization, but importantly does not negatively impact treatment response or survival in MCL patients.

Palbociclib plus venetoclax shows preclinical synergy in ibrutinib-refractory MCL by downregulating MCL1, offering a chemo-free option for patients without RB1 deletion.